ALK and neoplasm: A lymph node biopsy at this stage confirmed poorly differentiated LUAD with genetic testing demonstrating wild-type EGFR exons (18-21) and ALK. Notably, the local hospital omitted tumor marker assessment (e.g., carcinoembryonic antigen) and immunohistochemical analysis of biopsy specimens.